Liraglutide

Endocrinology

Endocrinology · GLP-1 receptor agonist

Liraglutide

Dose

0.6 mg SC OD × 1 wk → 1.2 mg → 1.8 mg OD (3.0 mg for obesity).

Contraindications

  • Personal/family MEN2 or medullary thyroid cancer

Use

T2DM with obesity/ASCVD; weight management.

Monitoring

Weight, HbA1c, GI tolerance, pancreatitis, thyroid nodule history.

Side effects

  • Nausea, vomiting
  • Diarrhoea
  • Gallstones
  • Injection-site reaction

Related in WardRound

Always confirm dose against your local formulary / BNF before prescribing.

WardRound

WardRound

Clinical Decisions in Seconds